Literature DB >> 16517250

Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal.

Anders Odén1, Martin Fahlén, Robert G Hart.   

Abstract

INTRODUCTION: Patients with nonvalvular atrial fibrillation are at increased risk for systemic embolism, predominantly disabling stroke. To study how stroke and mortality rates vary with different degrees of anticoagulation reflected by the international normalised ratio (INR) we critically assess information from different sources.
MATERIALS AND METHODS: 1. Computerized search of the medical literature published between 1980 and July 2004 was performed using MEDLINE applied to various combinations of the search terms of atrial fibrillation, warfarin, anticoagulation, anticoagulation intensity, and INR, not restricted by language. 2. We performed a record linkage analysis with death hazard estimated as a continuous function of INR based on 21,967 patients. Similarly the risk of admission to hospital or death due to diseases of the vessels of the brain was estimated. 3. Re-analysis of data earlier published by Hylek et al. from year 2003. RESULTS AND
CONCLUSIONS: 1. One randomised study showed a significantly lower risk of stroke for mean INR 2.4 compared to mean INR 1.3 combined with aspirin. Remaining studies found INRs of 2-2.5 to be as efficacious as higher anticoagulation intensities.2. Mortality as well as risk of admission to hospital or death due to diseases of the vessels of the brain followed U-shaped curves with minimum at INR 2.2 and 2.4, respectively. At high INR the risk increased 2.3 times per 1 unit increase of INR for death and 1.7 times for events in the vessels of the brain.3. The re-analysing of data of Hylek et al. indicated that there might be a substantial increase of the risk of intracranial hemorrhage when INR is increased from 2.5 to 4. We conclude that INRs in the interval 2.0--2.5 give the lowest risk of stroke and death in patients with nonvalvular atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16517250     DOI: 10.1016/j.thromres.2004.11.025

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  37 in total

1.  [Anticoagulation. Modern concepts].

Authors:  M Perrey; R Erbel
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

Review 2.  [New anticoagulants for stroke prevention in atrial fibrillation].

Authors:  H C Diener; K Hajjar; B Frank; M Perrey
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

Review 3.  Antithrombotic dose: Some observations from published clinical trials.

Authors:  Simon B Dimmitt; Christopher N Floyd; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-07-01       Impact factor: 4.335

4.  Unsuitable Comparison.

Authors:  Gerrit Müntefering
Journal:  Dtsch Arztebl Int       Date:  2020-10-30       Impact factor: 5.594

5.  Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.

Authors:  Shuhei Kobayashi; Koji Ishii; Yasuko Yamada; Emi Ryu; Junya Hashizume; Seiichi Nose; Tetsuya Hara; Mikiro Nakashima; Kaname Ohyama
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

6.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

Review 7.  Safety and efficacy of new anticoagulants in patients with heart failure.

Authors:  Ron Pisters; Gregory Y H Lip
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 8.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.

Authors:  Natalie Oake; Alison Jennings; Alan J Forster; Dean Fergusson; Steve Doucette; Carl van Walraven
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

9.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

10.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.